Skip to main content
. 2019 Sep 4;116(40):20054–20062. doi: 10.1073/pnas.1911842116

Fig. 4.

Fig. 4.

Fc effector function does not contribute to the protective activity of mAbs targeting the membrane proximal region of EBOV GP. To assess whether mAbs targeting the HR2 (5.6.c2618) or the MPER domains (9.6.3A06) of EBOV GP rely on Fc–FcγR interactions for their in vivo antiviral function, Fc domain variants of these mAbs with either diminished (GRLR) or enhanced (GASDALIE) affinity for the various human FcγRs were generated, and their protective activity was evaluated in FcγR humanized mice following lethal challenge with mouse-adapted EBOV (100 pfu 1 d post-mAb administration; 150 μg intraperitoneally). Protective activity of 5.6.c2618 (A) and 9.6.3A06 (B) was compared between wild-type human IgG1 and Fc variants to assess for FcγR dependence; n = 10 per experimental group. Log rank (Mantel–Cox) test. SI Appendix, Fig. S4 D and E shows mAb dose titration studies. ns, not significant.